Name | L-Norleucine |
Synonyms | H-Nle-OH L-Norleucine Glycoleucine L-nor-Leucine (S)-Norleucine n-C4H9CH(NH2)COOH Norleucine Solution Norleucine, L- (8CI) Alpha-Aminocaproic Acid alpha-aminocaproic acid Hexanoic acid, 2-amino-, (S)- |
CAS | 327-57-1 |
EINECS | 206-321-4 |
InChI | InChI=1/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1 |
Molecular Formula | C6H13NO2 |
Molar Mass | 131.17 |
Density | 1.1720 (estimate) |
Melting Point | >300 °C (lit.) |
Boling Point | 234.0±23.0 °C(Predicted) |
Specific Rotation(α) | 22 º (c=2, 6N HCl) |
Flash Point | 275 °C |
Water Solubility | 1.6 g/100 mL (23 ºC) |
Solubility | 1.6 g/100 mL (23°C) |
Vapor Presure | 0.0188mmHg at 25°C |
Appearance | Crystalline Powder |
Color | White to off-white |
Merck | 14,6706 |
BRN | 1721750 |
pKa | 2.335(at 25℃) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 23 ° (C=5, 5mol/L HC |
MDL | MFCD00064423 |
In vitro study | L-Norleucine is an isomer of leucine, specifically affecting protein synthesis in skeletal muscle. L-Norleucine has antiviral activity. L-Norleucine interacts with hnRNPA2/B1 protein to suppresses the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promotes the expression of E-cadherin, resulting in the inhibition of tumor metastasis. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 43 - May cause sensitization by skin contact |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S24/25 - Avoid contact with skin and eyes. S22 - Do not breathe dust. |
WGK Germany | 3 |
RTECS | RC6308000 |
TSCA | Yes |
HS Code | 29224995 |
Reference Show more | 1. [IF=3.765] Xia Xiaojing et al."Preparation and evaluation of a novel solid dispersion using leucine as carrier."J Pharm Pharmacol. 2020 Jan;72(2):175-184 |
sublimation point | 275°C |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
overview | unnatural amino acids are the core intermediates of many drugs, especially new drugs in the past 10 years. The production processes of unnatural amino acids such as L-n-leucine mainly include asymmetric synthesis, chemical resolution and biological enzyme catalysis. Among them, asymmetric synthesis is not widely used in industrial production due to the relatively expensive chiral catalysts and chiral auxiliary reagents; chemical resolution is gradually not in line with the current requirements of clean production due to the large consumption of raw materials, large pollution, and low chiral content; bioenzyme catalysis has the advantages of high stereoselectivity, mild reaction conditions, high chiral content, product serialization, and less pollution. It is the development direction of non-natural amino acid industrial production technology in the future. |
application | L-n-leucine is an amino acid derivative, which can be used as a pharmaceutical intermediate. |
Biological activity | L-Norleucine ((S)-2-Aminohexanoic acid) is an isomer of leucine, which can affect the synthesis of proteins in skeletal muscle. |
category | toxic substances |
flammability hazard characteristics | combustible; combustion produces toxic nitrogen oxide smoke |
storage and transportation characteristics | warehouse ventilation and low temperature drying |
fire extinguishing agent | water, carbon dioxide, dry powder, sand |